Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTR-01 Extension Study in RDEB
NCT05143190Phase 2Completed
- Sponsor
- Phoenix Tissue Repair
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RIN-002 in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Phoenix Tissue Repair. Primary endpoints: Sustained wound healing up to 246 days and Incidence of treatment-emergent adverse events up to 246 days. Started Dec 2021; status: completed.
02
Drugs
RIN-002
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT05143190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143190.